Search results for "muscarinic antagonists"

showing 10 items of 75 documents

Arginine vasopressin, via activation of post-junctional V1 receptors, induces contractile effects in mouse distal colon

2013

The aim of this study was to analyze whether arginine vasopressin (AVP) may be considered a modulator of intestinal motility. In this view, we evaluated, in vitro, the effects induced by exogenous administration of AVP on the contractility of mouse distal colon, the subtype(s) of receptor(s) activated and the action mechanism. Isometric recordings were performed on longitudinal and circular muscle strips of mouse distal colon. AVP (0.001 nM-100 nM) caused concentration-dependent contractile effects only on the longitudinal muscle, antagonized by the V1 receptor antagonist, V-1880. AVP-induced effect was not modified by tetrodotoxin, atropine and indomethacin. Contractile response to AVP was…

AtropineMaleReceptors Vasopressinmedicine.medical_specialtyVasopressinCarbacholNifedipineColonPhysiologyIndomethacinClinical BiochemistryMuscarinic AntagonistsTetrodotoxinCholinergic AgonistsIn Vitro TechniquesBiologyBiochemistryContractilityMiceCellular and Molecular Neurosciencechemistry.chemical_compoundPhosphoinositide Phospholipase CEndocrinologyInternal medicinemedicineAnimalsCyclooxygenase InhibitorsReceptorVasopressin receptorPhospholipase CArginine vasopressin receptor 1AMuscle SmoothCalcium Channel BlockersArginine vasopressinIntestinalcontractility V1 receptorsPhospholipase C Mouse colonArginine VasopressinEnzyme ActivationMice Inbred C57BLEndocrinologychemistryCarbacholGastrointestinal MotilityCyclopiazonic acidhormones hormone substitutes and hormone antagonistsMuscle ContractionSignal Transductionmedicine.drugRegulatory Peptides
researchProduct

Acetylcholine via Muscarinic Receptors Inhibits Histamine Release from Human Isolated Bronchi

1997

Human bronchi were incubated in organ baths to measure histamine release. The calcium ionophore A23187 (10 mumol/L; 1 min) stimulated histamine release by 148 +/- 28% (n = 11) above the prestimulation level but was ineffective in epithelium-denuded bronchi. Neither bradykinin (0.1 mumol/L) nor compound 48/80 (10 micrograms/ml) triggered the release of histamine from epithelium-intact bronchi. Acetylcholine did not affect spontaneous histamine release (about 2 nmol/g x 5 min) but inhibited A23187-evoked histamine release in an atropine-sensitive manner. Already a concentration as low as 0.1 nmol/L acetylcholine was effective, the maximal inhibition (by 89%) occurred at 100 nmol/L, whereas a …

AtropinePulmonary and Respiratory MedicineAgonistPhysostigminemedicine.medical_specialtyTime Factorsmedicine.drug_classPhysostigmineBradykininBronchiMuscarinic AntagonistsMuscarinic AgonistsCritical Care and Intensive Care MedicineHistamine Releasechemistry.chemical_compoundCulture TechniquesInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansDrug InteractionsCalcimycinDose-Response Relationship DrugIonophoresbusiness.industryOxotremorineImmunoglobulin EReceptors MuscarinicAcetylcholineEndocrinologychemistryAcetylcholinesterase inhibitorDepression ChemicalCholinesterase InhibitorsbusinessAcetylcholineHistaminemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Use of atropine-treated Daphnia magna survival for detection of environmental contamination by acetylcholinesterase inhibitors.

2003

The toxicity of cholinesterase-inhibiting compounds (e.g., carbamates and organophosphates) is due to a decrease in acetylcholine metabolism, which results in a continuous stimulation of cholinergic receptors (muscarinic and nicotinic) that can be fatal. The goal of this study was to evaluate the protective effect of atropine (muscarinic receptor antagonist) against paraoxon-induced toxicity to Daphnia magna using its survival rate for the detection of environmental contamination by cholinesterase-inhibiting compounds. As expected, paraoxon was lethal to D. magna in a concentration-dependent manner. Noteworthy, the pretreatment of these organisms with atropine dramatically increased their s…

AtropineSurvivalHealth Toxicology and MutagenesisDaphnia magnaMuscarinic AntagonistsBiologyPharmacologyParaoxonToxicologychemistry.chemical_compoundMuscarinic acetylcholine receptormedicineAnimalsreproductive and urinary physiologyParaoxonfungiPublic Health Environmental and Occupational HealthGeneral Medicinebiology.organism_classificationPollutionAcetylcholinesteraseAtropineNicotinic agonistchemistryDaphniaToxicityCholinergicCholinesterase InhibitorsBiomarkersWater Pollutants Chemicalmedicine.drugEcotoxicology and environmental safety
researchProduct

Receptor phosphorylation does not mediate cross talk between muscarinic M(3) and bradykinin B(2) receptors.

1999

This study examined cross talk between phospholipase C-coupled muscarinic M3and bradykinin B2receptors coexpressed in Chinese hamster ovary (CHO) cells. Agonists of either receptor enhanced phosphoinositide signaling (which rapidly desensitized) and caused protein kinase C (PKC)-independent, homologous receptor phosphorylation. Muscarinic M3but not bradykinin B2receptors were also phosphorylated after phorbol ester activation of PKC. Consistent with this, muscarinic M3receptors were phosphorylated in a PKC-dependent fashion after bradykinin B2receptor activation, but muscarinic M3receptor activation did not influence bradykinin B2receptor phosphorylation. Despite heterologous phosphorylatio…

Atropinemedicine.medical_specialtyReceptor Bradykinin B2PhysiologyGene ExpressionCHO CellsInositol 145-TrisphosphateMuscarinic AntagonistsBiologyMuscarinic AgonistsBradykininTransfectionTritiumInternal medicineCricetinaeMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4AnimalsHumansBradykinin receptorPhosphorylationReceptorMethacholine ChlorideReceptor Muscarinic M3Receptors BradykininMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Cell BiologyMuscarinic acetylcholine receptor M1Receptor Cross-TalkReceptors MuscarinicRecombinant ProteinsEndocrinologyType C PhospholipasesCalciumInositolSignal TransductionThe American journal of physiology
researchProduct

The non-neuronal cholinergic system in peripheral blood cells: Effects of nicotinic and muscarinic receptor antagonists on phagocytosis, respiratory …

2007

Peripheral blood cells express the complete non-neuronal cholinergic system. For example synthesis of acetylcholine and nicotinic as well muscarinic receptors have been demonstrated in leucocytes isolated from human peripheral blood. In the present experiments mononuclear cells and granulocytes were isolated from the peripheral blood to investigate content and synthesis of acetylcholine as well as phenotypic functions like respiratory burst, phagocytosis and migration. Mononuclear cells (T-cells and monocytes) contained 0.36 pmol/10(6) cells acetylcholine, whereas acetylcholine content in granulocytes was 100-fold lower. Acetylcholine synthesis amounted to 23.2+/-4.7 nmol/mg protein/h and 2…

Atropinemedicine.medical_specialtyTubocurarineMuscarinic AntagonistsNicotinic AntagonistsBiologyHexamethoniumGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundPhagocytosisCell MovementInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M4medicineHumansGeneral Pharmacology Toxicology and PharmaceuticsChromatography High Pressure LiquidRespiratory BurstNeuronsDose-Response Relationship DrugMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineMuscarinic acetylcholine receptor M1BungarotoxinsAcetylcholineEndocrinologyNicotinic agonistchemistryLeukocytes MononuclearHexamethoniumAcetylcholineGranulocytesmedicine.drugLife Sciences
researchProduct

Plasma concentration following oral and intramuscular atropine in children and their clinical effects.

1997

In a paediatric population, we compared i.m. v oral atropine premedication to a control group without atropine and determined atropine plasma concentrations (APC). Forty-five children were randomly assigned to one of three groups. Group I received atropine, 20 micrograms.kg-1 i.m., 15 min prior to induction. Group II received atropine, 30 micrograms.kg-1 orally, group III received no atropine. APC (expressed as percent of muscarine-2 receptor subtype occupancy), heart rate, rectal temperature, and salivation were determined before atropine, and 15, 25, 45, 60, 90, 120 (no APC), and 150 min following atropine. Only 10-20% of the M2-cholinoceptors were occupied after oral atropine with a peak…

BradycardiaAtropineMalemedicine.medical_specialtyGroup iiAdministration OralMuscarinic AntagonistsInjections IntramuscularReceptor subtypeBody TemperatureHeart RateInternal medicineHeart rateMedicineHumansChildReceptor Muscarinic M2business.industryReceptors MuscarinicAtropineAnesthesiology and Pain MedicineEndocrinologyAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthPlasma concentrationPremedicationFemalemedicine.symptombusinessSalivationPreanesthetic MedicationPaediatric populationmedicine.drugPaediatric anaesthesia
researchProduct

Ability of short-time Fourier transform method to detect transient changes in vagal effects on hearts: a pharmacological blocking study.

2006

Conventional spectral analyses of heart rate variability (HRV) have been limited to stationary signals and have not allowed the obtainment of information during transient autonomic cardiac responses. In the present study, we evaluated the ability of the short-time Fourier transform (STFT) method to detect transient changes in vagal effects on the heart. We derived high-frequency power (HFP, 0.20–0.40 Hz) as a function of time during active orthostatic task (AOT) from the sitting to standing posture before and after selective vagal (atropine sulfate 0.04 mg/kg) and sympathetic (metoprolol 0.20 mg/kg) blockades. The HFP minimum point during the first 30 s after standing up was calculated and…

Cardiac responseAdultAtropineMalemedicine.medical_specialtySympathetic Nervous SystemPhysiologyAdrenergic beta-AntagonistsPostureBlood PressureMuscarinic AntagonistsDizzinessOrthostatic vital signsPhysiology (medical)Internal medicinemedicineHeart rate variabilityHumansFourier AnalysisChemistryBlocking (radio)Short-time Fourier transformHeartVagus NerveAutonomic AgentsTime–frequency analysisSurgeryAutonomic nervous systemCardiologyTransient (oscillation)Cardiology and Cardiovascular MedicineMetoprololAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Loss of input from the mossy cells blocks maturation of newly generated granule cells.

2007

The objective of this work is to check whether the input from the mossy cells to the inner molecular layer is necessary for the integration and maturation of the newly generated granule cells of the dentate gyrus (DG) in mice, and if after status epilepticus the sprouting of the mossy fibers can substitute for this projection. Newly generated cells were labeled by administration of 5-bromo-deoxyuridine either before or after pilocarpine administration. The neuronal loss in the hippocampus after administration of pilocarpine combined with scopolamine and diazepam seemed restricted to the hilar mossy cells. The maturation of the granule cells was studied using immunohistochemistry for calreti…

Cell typeCell SurvivalCognitive NeuroscienceScopolamineConvulsantsNerve Tissue ProteinsMuscarinic Antagonistschemistry.chemical_compoundMiceS100 Calcium Binding Protein GStatus EpilepticusmedicineAnimalsCell ProliferationDiazepamEpilepsyNeuronal PlasticitybiologyChemistryDentate gyrusStem CellsGranule (cell biology)PilocarpineNuclear ProteinsCell DifferentiationImmunohistochemistryDNA-Binding Proteinsnervous systemBromodeoxyuridinePilocarpineCalbindin 2Dentate GyrusMossy Fibers HippocampalNerve Degenerationbiology.proteinAnticonvulsantsFemaleNeuNCalretininNeuroscienceBromodeoxyuridineBiomarkersSproutingmedicine.drugHippocampus
researchProduct

Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels

2015

Storage dysfunction of the urinary bladder, specifically overactive bladder syndrome, is a condition that occurs frequently in the general population. Historically, pathophysiological and treatment concepts related to overactive bladder have focused on smooth muscle cells. Although these are the central effector, numerous anatomic structures are involved in their regulation, including the urothelium, afferent and efferent nerves, and the central nervous system. Each of these structures involves receptors for—and the urothelium itself also releases—many mediators. Moreover, hypoperfusion, hypertrophy, and fibrosis can affect bladder function. Established treatments such as muscarinic antago…

Central Nervous Systemmedicine.medical_specialtyUrinary BladderPopulationCentral nervous systemMuscarinic Antagonistsurologic and male genital diseasesToxicologyBioinformaticsMuscle hypertrophyNeurons EfferentFibrosisInternal medicinemedicineAnimalsHumansNeurons AfferentUrotheliumeducationPharmacologyeducation.field_of_studyUrinary bladderbusiness.industryUrinary Bladder DiseasesMuscle SmoothAdrenergic beta-AgonistsHyperplasiamedicine.diseasefemale genital diseases and pregnancy complicationsUrodynamicsTreatment OutcomeEndocrinologymedicine.anatomical_structureOveractive bladderAdrenergic alpha-1 Receptor AntagonistsUrological AgentsUrotheliumbusinessSignal TransductionAnnual Review of Pharmacology and Toxicology
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7…

ExacerbationReviewQuinoloneslaw.inventionPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineRandomized controlled trialsystematic reviewlaw030212 general & internal medicineCOPDLABA LAMA fixed-dose combination COPD systematic reviewbiologyHealth PolicyOlodaterolLAMAGeneral MedicineLamaRespiratory Function Testsfixed-dose combinationDrug CombinationsTreatment OutcomeIndanssystematic review.hormones hormone substitutes and hormone antagonistsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationLABA; LAMA; fixed-dose combination; COPD; systematic reviewLABAMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansCOPDAdverse effectAdrenergic beta-2 Receptor Agonistslcsh:RC705-779business.industryPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemCOPD; LABA; LAMA; fixed-dose combination; systematic reviewmedicine.diseasebiology.organism_classificationGlycopyrrolate030228 respiratory systemchemistryDelayed-Action PreparationsIndacaterolbusiness
researchProduct